However, the association of CD56+ T cells with MS pathogenesis has not been widely recognized likely because, as shown here, CD56+ T cells were not increased in patients who did not receive fingolimod therapy, regardless of remission or relapse, and most of the CD56+ T cells were CCR7-negative, despite that encephalitogenic cells are thought to belong to TCM expressing CCR712, 26. Here, NCAM1 is linked to myeloid sarcoma.